Engineers Gate Manager’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$116K Sell
38,037
-78,075
-67% -$233K ﹤0.01% 2050
2026
Q1
$358K Buy
116,112
+28,848
+33% +$122K ﹤0.01% 1614
2025
Q4
$315K Buy
87,264
+46,221
+113% +$202K ﹤0.01% 1611
2025
Q3
$155K Buy
+41,043
New +$158K ﹤0.01% 1955
2025
Q1
Sell
-14,414
Closed -$104K 2122
2024
Q4
$104K Buy
+14,414
New +$110K ﹤0.01% 1992
2023
Q4
Sell
-23,355
Closed -$60.7K 1947
2023
Q3
$60.7K Sell
23,355
-4,120
-15% -$11.8K ﹤0.01% 1642
2023
Q2
$97K Buy
+27,475
New +$123K ﹤0.01% 1572
2022
Q2
Sell
-14,365
Closed -$87K 1872
2022
Q1
$87K Buy
+14,365
New +$106K ﹤0.01% 1724
2021
Q3
Sell
-13,929
Closed -$137K 1609
2021
Q2
$137K Buy
13,929
+1,113
+9% +$15.2K 0.01% 1458
2021
Q1
$181K Sell
12,816
-12,931
-50% -$209K 0.01% 1624
2020
Q4
$290K Buy
25,747
+14,847
+136% +$175K 0.01% 1312
2020
Q3
$144K Buy
+10,900
New +$218K 0.01% 1491

Other funds holding ALT

Engineers Gate Manager's ALT Position: Q2 2026 in Review

Engineers Gate Manager reduced its Altimmune (ALT) stake by 67% in Q2 2026, selling an estimated $233K and leaving 38,037 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Engineers Gate Manager first reported a position in ALT in Q3 2020 and has held it in 12 quarters since. The position peaked at $358K in Q1 2026. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Engineers Gate Manager held 38,037 shares of Altimmune worth $116K as of Q2 2026.
  • Engineers Gate Manager sold 78,075 Altimmune shares in Q2 2026, an estimated $233K.
  • Altimmune made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #2050 holding.
  • Engineers Gate Manager first reported a position in Altimmune in Q3 2020 and has held it in 12 quarters since.
  • Engineers Gate Manager's Altimmune position peaked at $358K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.